A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The primary objective of this study is to characterize the safety and tolerability of
loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or
mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose
for expansion (RDE) for the combinations.

Inclusion Criteria:

- Male or female participant aged 18 years or older

- Pathologic diagnosis of relapsed (disease that has recurred following a response) or
refractory (disease that failed to respond to prior therapy) B-NHL (2016 World
Health Organization classification) who have failed, or been intolerant to any
approved therapy and had received at least two systemic treatment regimens in
dose-escalation part; and at least one systemic treatment regimen in dose-expansion
part

- Aggressive B Cell Lymphomas:

- DLBCL (including transformed diseases, but for Arms E and F, including
transformed FL only)

- HGBCL

- FL Grade 3b

- Indolent NHL:

- FL (Grade 1-3a)

- MZL

- For Arm C only:

- MCL

- BL

- Life expectancy of at least 24 weeks according to Investigator's judgement

- Need of systemic treatment for any of the listed indications as assessed by the
investigator, including indolent B-NHLs (e.g. FL and MZL)

- Measurable disease as defined by the 2014 Lugano Classification

- Availability of formalin-fixed paraffin-embedded tumor tissue block

- ECOG performance status 0 to 2

- Adequate organ function

- Women of childbearing potential (WOCBP) must agree to use a highly effective method
of contraception from the time of giving informed consent until at least 10 months
after the last dose of loncastuximab tesirine. Men with female partners who are of
childbearing potential must agree to use a condom when sexually active or practice
total abstinence from the time of giving informed consent the first dose until at
least 7 months after the last dose of loncastuximab tesirine. Men must refrain from
donating sperm during this same period. For the arm that includes glofitamab, WOCBP
must agree to use contraceptive methods that result in a failure of less than 1% per
year or remain abstinent (refrain from heterosexual intercourse) during the
treatment period and for at least 18 months after pretreatment with obinutuzumab.
For the arm that includes mosunetuzumab, WOCBP must agree to use contraceptive
methods that result in a failure of less than 1% per year or remain abstinent
(refrain from heterosexual intercourse) during the treatment period and for at least
3 months after the final dose of mosunetuzumab and tocilizumab (if applicable).

Exclusion Criteria:

- Known history of hypersensitivity resulting in treatment discontinuation to or
positive serum human ADA to a CD19 antibody

- Previous therapy with loncastuximab tesirine

- Previous treatment with polatuzumab vedotin, glofitamab or mosunetuzumab (applied to
relevant arm and/or cohort of the specific drug administered)

- Participants who received previous treatment of polatuzumab vedotin containing
regimen will be excluded from Arm C

- Participants who received previous treatment of glofitamab containing regimen
will be excluded from Arm E

- Participants who received previous treatment of mosunetuzumab containing
regimen will be excluded from Arm F

- Allogenic or autologous stem cell transplant within 60 days prior to start of study
drug (C1 D1)

- Human immunodeficiency virus (HIV) seropositive

- Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or
unwilling to receive standard prophylactic antiviral therapy or with detectable HBV
viral load

- Serologic evidence of hepatitis C virus (HCV) infection without completion of
curative treatment or with detectable HCV viral load

- History of confirmed progressive multifocal leukoencephalopathy

- History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or macrophage
activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH)

- Lymphoma with active central nervous system (CNS) involvement at the time of
screening, including leptomeningeal disease

- Clinically significant third space fluid accumulation (i.e., ascites requiring
drainage or pleural effusion that is either requiring drainage or associated with
shortness of breath)

- Breastfeeding or pregnant

- Significant medical comorbidities

- Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy, within
14 days prior to start of study drugs (C1 D1), except shorter if approved by the
Sponsor

- Live vaccine within 4 weeks prior to C1D1

- Failure to recover to Grade ≤1 (Common Terminology Criteria for Adverse Events
[CTCAE] version 5.0) from acute non-hematologic toxicity (Grade ≤2 alopecia) due to
previous therapy prior to screening

- Active second primary malignancy other than non-melanoma skin cancers,
non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma
in situ of the breast, or other malignancy that the Sponsor's medical monitor and
Investigator agree and document should not be exclusionary

Extra Exclusion Criteria for Arms E (includes glofitamab) and F (includes mosunetuzumab)
Note: as applicable, the arm-specific exclusion criteria may supersede the general ones,
such as stem cell transplant.

- Prior allogeneic stem cell transplant and solid organ transplant

- Autologous stem cell transplant within 100 days prior to C1D1

- History of CNS lymphoma or leptomeningeal infiltration

- Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or
neurodegenerative disease

- Known active infection, reactivation of a latent infection, whether bacterial,
viral, fungal, mycobacterial, or other pathogens (excluding fungal infections of
nail beds), or any major episode of infection requiring hospitalization or treatment
with intravenous (IV) antibiotics within four weeks prior to C1D1

- Active or history of autoimmune disease or immune deficiency, motor neuropathy
considered of autoimmune origin and other central nervous system (CNS) autoimmune
diseases, including but not limited to, myasthenia gravis, myositis, autoimmune
hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel
disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren
syndrome, Guillain-Barré syndrome, or multiple sclerosis, with, with certain
exceptions

- Prior treatment with anti-cancer/lymphoma targeted therapies (e.g., tyrosine kinase
inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not
limited to, cluster of differentiation 137 agonists or immune checkpoint blockade
therapies, including anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4),
anti-programmed cell death protein 1 (PD1), and anti-programmed death ligand 1
(PDL1) therapeutic antibodies, radio-immunoconjugates, ADCs, immune/cytokines and
monoclonal antibodies) or treatment with systemic immunosuppressive medication
(including, but not limited to, cyclophosphamide, azathioprine, methotrexate,
thalidomide, and anti-tumor necrosis factor agents) within 4 weeks or five
half-lives of the drug, whichever is shorter, prior to C1D1, or anticipation of need
for systemic immunosuppressive medication during study treatment, with certain
exceptions

- Prior treatment with CAR-T-cell therapy within 100 days prior to C1D1; primary
refractory patients (progressive or persistent disease within 30 days) to CAR-T-cell
therapy are not eligible.

- Toxicities from prior anti-cancer therapy including immunotherapy that did not
resolve to ≤ Grade 1 with the exception of alopecia, endocrinopathy managed with
replacement therapy and stable vitiligo

- Any history of immune-related Grade ≥3 AE with the exception of endocrinopathy
managed with replacement therapy

- Ongoing corticosteroid use greater than 25 mg/day of prednisone or equivalent within
4 weeks prior and during study treatment

- Administration of a live attenuated vaccine within 4 weeks prior to the first dose
of study treatment or anticipation that such a live attenuated vaccine will be
required during the study or within 5 months after last dose of study treatment

Extra Exclusion Criteria for Arm E (includes glofitamab) only.

• Known history of hypersensitivity to obinutuzumab